Barrier posts Phase II results for antifungal drug

Barrier Therapeutics is reporting positive results from an ongoing Phase IIa study of pramiconazole, an oral antifungal treatment for patients with nail fungus. Patients enrolled in the study have shown a marked clinical improvement in total signs and symptoms of onychomycosis after 16 weeks of study. Full results from the study will be presented at a future scientific meeting. Pramiconazole may also be effective for a variety of other diseases, include tinea pedis (athlete's foot), tinea corporis (ring worm), tinea cruris, tinea versicolor, vaginal candidiasis and seborrheic dermatitis.

- take a look at Barrier's release

Related Articles:
Barrier reports positive data. Report
Barrier dermatitis treatment rejected by FDA. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.